Table 3.

CSE, analgesia and side effects for all enrolled women (treatment-received, n = 158)

Variable	Group A (N = 110)	Group G (N = 48)	p-Value
Rejected (>8 cm within 1 h of CSE)	8	9	0.048
VRS at CSE placement (0–10 cm)	9 [8,10]	9 [8,10]	0.15
Pruritus (0–3; 4 point scale)	1 [0,1]	0 [0,1]	>0.20
Nalbuphine (given after 60 min for pruritus) (n)	4	1	>0.20
Ephedrine use (n)	6	4	>0.20
Fetal bradycardia with uterine hypertonus (n)	3*	1**	>0.20

Data are presented as count and median [interquartiles].

Group A: 304A homozygotes.

Group G: 304A/G heterozygotes (n = 40) and 304G homozygotes (n = 8).

VRS: visual rating scale for pain intensity (0 = no pain, 10 = worst pain imaginable).

Pruritus scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe requiring nalbuphine.

Fetal bradycardia (FHR <100 bpm for more than 90 s) with uterine hypertonus (2 contractions lasting ⩾ 60 s) occurring within 15 min after spinal injection

^*doses: 22, 27 and 30 μg in Group A;

^**dose 14.5 μg in Group G; all 4 cases in spontaneous labor.